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AE = adverse event(s)
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aminotransferase
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FH = familial
hypercholesterolemia
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HDL = high-density
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ISR = injection site reaction
LDL = low-density lipoprotein
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T2DM = type 2 diabetes
mellitus
VLDL = very-low-density
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JACC Vol. 62, No. 23, 2013 Thomas et al.
December 10, 2013:2178–84 Mipomersen Reduces Atherogenic Lipoproteins
2179management to reduce CHD risk. Among high-risk patients
with known CHD, the guidelines recommend an LDL
cholesterol level of <100 mg/dl (3). However, conventional
lipid-lowering therapies often result in insufﬁcient LDL
cholesterol reductions, even when administered at maximally
tolerated doses (4).
Apolipoprotein B (apoB) is an essential component of
very-low-density lipoprotein (VLDL), intermediate-density
lipoprotein, LDL, and lipoprotein(a) (Lp[a]), with 1
molecule of apoB present in each lipoprotein particle. ApoB
is constitutively expressed in the liver. The consequences
of pharmacologic inhibition of apoB synthesis are unknown
and include the potential of hepatic compensation via
increased beta oxidation of hepatic lipid, as well as steatosis.
Mipomersen, an antisense oligonucleotide, decreases apoB
synthesis by inhibition of messenger ribonucleic acid trans-
lation (Fig. 1) (5–7). Mipomersen has signiﬁcantly reduced
LDL, apoB, and Lp(a) in patients with homozygous familial
hypercholesterolemia (FH) and moderate or severe hetero-
zygous FH (8–10). We evaluated the safety and efﬁcacy
of mipomersen compared with placebo in patients with
hypercholesterolemia with, or at high risk for, CHD already
receiving a maximally tolerated lipid-lowering regimen.Figure 1 Mipomersen Mechanism of Action
Mipomersen is a second-generation antisense oligonucleotide (ASO) that inhibits
the synthesis of apolipoprotein B-100 (apoB-100) by binding to the cognate apoB
messenger ribonucleic acid (mRNA) through Watson-Crick base pairs to form
a substrate for ribonuclease H (RNase H), a ubiquitously expressed nuclease,
which preferentially hydrolyzes the ribonucleic acid (RNA) strand of a RNA:deoxyr-
ibonucleic acid (DNA) duplex. Second-generation ASOs are synthetic phosphor-
othioate-modiﬁed oligodeoxynucleotides with 20 -O-(2-methoxyelthyl)-D-ribose
(20 -MOE) modiﬁed nucleotides incorporated into a portion of the ASO for increased
afﬁnity toward the target RNA and greater resistance to exonuclease and endo-
nuclease activity, while maintaining a 20 -deoxy domain to support RNase H activity.
The net result from incorporation of the 20 -MOE modiﬁcation is an increase in
antisense drug potency and durability and an associated attenuation of off-target
class effects. Inhibition of apoB mRNA translation takes place in the cytoplasm.
Binding of mipomersen to apoB mRNA and RNase H activit, can occur either
in the nucleus or cytoplasm. LDL-C ¼ low-density lipoprotein cholesterol;
VLDL ¼ very-low-density lipoprotein.This is the ﬁrst phase 3 evalua-
tion of mipomersen in patients
without FH.
Methods
This prospective, randomized,
double-blind, placebo-controlled
study was conducted at 62 U.S.
centers between November 2008
and October 2010. After provid-
ing informed consent and under-
going screening, eligible patients
were randomized (2:1) to mipo-
mersen 200 mg or placebo. Ran-
domization was stratiﬁed so that
a minimum number of patients
(40%) would have type 2 diabetes
mellitus (T2DM). Medication was
administered as a single, subcu-
taneous injection once weekly for
26 weeks, allowing assessment at
steady-state levels of mipomersen given its half-life of approx-
imately 31 days (7). Patients then entered a 24-week safety
follow-up. This trial (NCT00770146) was approved by all
ethics boards and conducted according to Good Clinical
Practice and International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals
for Human Use guidelines.
Men and nonpregnant, nonlactating women age
18 years with hypercholesterolemia (fasting LDL cho-
lesterol 100 mg/dl, triglyceride <200 mg/dl) with, or at
high risk for, CHD (per National Cholesterol Education
Program Adult Treatment Panel III guidelines) were eligible
(3). At screening, all patients were at stable weights, on
low-fat diets, and receiving lipid-lowering regimens that
included a maximally tolerated statin dose. Major exclusion
criteria included signiﬁcant cardiovascular or cerebrovas-
cular events within 24 weeks of screening, congestive heart
failure, type 1 diabetes, uncontrolled hypertension, any
disorder known to predispose to secondary hyperlipidemia,
or a history of renal or hepatic disease. Patients were not
permitted to alter their lipid-lowering regimens for 28
weeks.
Patients were evaluated at baseline and every other week
for the ﬁrst 9 weeks, every 4 to 5 weeks for the remainder
of treatment, and 4 times during follow-up. Laboratory
assessments and statistical analysis were similar to a previ-
ously published trial (8), as described in Online Appendix A.
The primary outcome was percent reduction in LDL
cholesterol from baseline to the primary efﬁcacy timepoint,
deﬁned as the post-baseline visit closest to 14 days after the
last dose of medication (week 28). Additional efﬁcacy
outcomes included percent changes in apoB, total choles-
terol, non–high-density lipoprotein (HDL) cholesterol,
triglyceride, Lp(a), VLDL cholesterol, LDL/HDL ratio,
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2180apolipoprotein A-I, and HDL cholesterol. An exploratory
analysis of lipoprotein particles occurred.Results
Online Figure 1 displays patient ﬂow. At baseline, among
patients who received the study treatment (n ¼ 157), 72%
had metabolic syndrome (11), 56% had T2DM, and 52%
had CHD or other atherosclerotic disease. All patients were
receiving lipid-lowering medications, including statins; 43%
were receiving the maximal U.S. Food and Drug Admin-
istration–approved statin dose. Patients were typically
middle aged, white, and overweight, with a mean body mass
index of 30.4  4.6 kg/m2 (Table 1). Groups were well
balanced in demographics and baseline characteristics; there
were no clear differences between patients with and without
T2DM.
Mean LDL cholesterol was elevated at baseline: 122.6 
31.7 mg/dl in the mipomersen group and 122.7 
38.6 mg/dl in the placebo group (Table 2). At the primary
efﬁcacy timepoint, mipomersen-treated patients experienced
signiﬁcantly greater reductions from baseline in mean LDL
cholesterol (36.9%) than placebo-treated patients (4.5%)
(p < 0.001) (Fig. 2). Moreover, 76% of mipomersen versusTable 1 Demographics and Baseline Characteristics
Parameter*
Placebo
(n ¼ 52)
Mipomersen
(n ¼ 105)
Age (yrs) 59.3  9.5 59.3  10.0
Men/women 29 (55.8%)/23 (44.2%) 52 (49.5%)/53 (50.5%)
Race/ethnicity
White 40 (76.9%) 83 (79.0%)
Black 11 (21.2%) 20 (19.0%)
Hispanic or Latino 9 (17.3%) 16 (15.2%)
American Indian
or Alaskan Native
1 (1.9%) 1 (1.0%)
Other 0 (0.0%) 1 (1.0%)
BMI (kg/m2) 30.0  4.4 30.7  4.6
Metabolic syndromey 40 (76.9%) 73 (69.5%)
Current smoker 11 (21.2%) 18 (17.1%)
T2DM 30 (57.7%) 58 (55.2%)
Cardiovascular history
Angina 5 (9.6%) 9 (8.6%)
CHDz 21 (40.4%) 52 (49.5%)
Other clinical
atherosclerotic
diseasex
3 (5.8%) 11 (10.5%)
Lipid-lowering regimen
Any statin 52 (100.0%) 105 (100.0%)
Maximal
FDA-approved
statin dose
20 (38.5%) 43 (41.0%)
Statin plus other 32 (61.5%) 58 (55.2%)
Values are mean  SD or n (%). yMetabolic syndrome was determined according to the American
Heart Association and the National Heart, Lung, and Blood Institute deﬁnition (11). zIncludes
myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention,
and coronary artery disease without event. xIncludes peripheral artery disease, abdominal aortic
aneurysm, and carotid artery disease.
BMI ¼ body mass index; CHD ¼ coronary heart disease; FDA ¼ U.S. Food and Drug Adminis-
tration; T2DM ¼ type 2 diabetes mellitus.38% of placebo patients attained LDL cholesterol <100
mg/dl at the primary efﬁcacy timepoint, while 51% of
mipomersen versus 8% of placebo attained LDL cholesterol
<70 mg/dl. Substantial reductions in mean LDL cholesterol
(17%) were seen by week 5, with near maximal effects
observed by week 17, consistent with a half-life of approx-
imately 31 days (7); after treatment completion (week 26),
LDL cholesterol gradually increased and returned to base-
line by week 50 (Fig. 3).
The effect of mipomersen was greater in women and
patients older than 59 years (mean/median age) compared
with men and patients younger than 59 years, whose lipid
lowering was still clinically meaningful and statistically
signiﬁcant. The mean percent changes in LDL cholesterol
were 32.7  25% and 41.2  28.3% for male and female
mipomersen patients, respectively, compared with placebo
at 8.6  26.6% and 1.1  19.7%. The mean percent
changes in LDL cholesterol were 29.8  30.3%
and 41.8  23.3% for mipomersen patients younger and
older than 59 years, respectively, compared with 7.4 
25.2% and 1.9  23.5% for placebo. Baseline LDL
cholesterol and race did not inﬂuence treatment effect.
Reductions from baseline to the primary efﬁcacy
timepoint in apoB, non-HDL cholesterol, and LDL/HDL
ratio were similar (about 37%) to those in LDL cholesterol;
reductions in total cholesterol, triglyceride, and VLDL
cholesterol were slightly smaller (about 25%) (Table 2,
Fig. 3). Lp(a), not typically affected by statins, ezetimibe, or
bile acid sequestrants (12), was also reduced (26% with
mipomersen, 0% with placebo). A small decrease in apoli-
poprotein A-I was observed with mipomersen. No signiﬁ-
cant difference was noted between treatment groups in
HDL cholesterol or high-sensitivity C-reactive protein. As
with LDL cholesterol, all lipids and lipoproteins gradually
returned to baseline after treatment cessation. Baseline levels
of lipids and lipoproteins and changes in lipids and lipo-
proteins associated with mipomersen treatment were similar
regardless of diabetic status (Table 3).
In an exploratory analysis, lipoprotein particle concen-
trations were determined using nuclear magnetic resonance
spectroscopy. As in previous studies (13,14) greater reduc-
tions were noted in the number of small (542.5 nmol/l)
versus large LDL particles (79.7 nmol/l) in the mipo-
mersen group; no meaningful changes occurred in the
placebo group (small, 54.1 nmol/l; large, 22.6 nmol/l).
The most common adverse events (AEs) related to
tolerability were injection site reactions (ISRs) and ﬂu-like
symptoms (FLS). The incidence of ISRs was greater with
mipomersen (78.1%) compared with placebo (30.8%), as
was the incidence of FLS (34.3% vs. 21.2%) (Table 4).
The most common AEs related to safety were elevated
liver enzyme levels and increased liver fat. Alanine
aminotransferase (ALT) increased in more mipomersen
patients compared with placebo but trended toward base-
line after week 26 (Fig. 4). Ten mipomersen patients had
ALT levels 3 times the upper limit of normal on 2
Table 2 Effect of Treatment on Lipid Parameters
Parameter
Placebo (n ¼ 50) Mipomersen (n ¼ 101)
Baseline PET
% Change,
Baseline to PET Baseline PET
% Change,
Baseline to PET*
LDL cholesterol (mg/dl) 122.7  38.6 113.3  35.1 4.5  24.22 122.6  31.7 75.3  32.4 36.9  26.85
ApoB (mg/dl) 115.7  30.1 109.1  27.2 4.1  18.09 117.1  25.2 72.8  30.7 37.5  23.59
Lp(a) (mg/dl) 31 (11, 76) 33 (10, 78) 0.0 (16.0, 17.6) 36 (10, 85) 21 (6, 54) 25.6 (40.0, 7.8)
TC (mg/dl) 200.0 (42.1) 192.2 (38.3) 2.7  14.58 202.6  36.8 147.4  39.9 26.4  18.65
Non-HDL cholesterol (mg/dl) 151.6  44.4 143.2  38.7 3.1  20.43 151.8  35.1 96.3  38.3 35.7  23.75
HDL cholesterol (mg/dl) 48.4  15.9 48.9  16.1 2.2  16.44 50.8  12.0 51.1  12.3 2.2  17.99
TG (mg/dl) 144.6  66.1 152.9  97.5 11.3  53.26 146.7  65.3 105.0  55.7 25.2  29.21
VLDL cholesterol (mg/dl) 28.9  13.2 29.9  16.3 10.7  53.83 29.2  12.1 21.0  11.1 25.3  28.75
ApoA1 (mg/dl) 150.8  30.5 147.8  27.3 1.0  11.16 156.8  25.4 146.8  24.5 5.6  12.56
LDL/HDL ratio 2.8  1.4 2.5  1.1 5.27  25.31 2.5  0.9 1.5  0.8 37.36  27.2
Values are mean  SD or median (25th percentile, 75th percentile). *p < 0.001, mipomersen versus placebo, except HDL cholesterol (p ¼ 0.977) and apoA1 (p ¼ 0.032). P values were calculated for the
between-group comparisons of percent changes from baseline to PET, which were obtained using Student t tests for all parameters except LDL cholesterol, apoB, non-HDL cholesterol, TG, and VLDL
cholesterol, for which the Wilcoxon rank sum test was used because of deviations from normality.
ApoA1 ¼ apolipoprotein A1; apoB ¼ apolipoprotein B; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; Lp(a) ¼ lipoprotein(a); PET ¼ primary efﬁcacy timepoint; TC ¼ total cholesterol; TG ¼
triglycerides; VLDL ¼ very-low-density lipoprotein.
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2181consecutive measures at least 7 days apart; no concomitant
increases in bilirubin or changes in liver synthetic function
occurred.
The mean of absolute changes in average liver fat fraction
from baseline to end of treatment was 15.9  11.2% for
mipomersen (n¼ 48) versus 0.6 7.1% for placebo (n¼ 33)
(Table 5). The mean liver fat fraction remained unchanged
at the end of the week 24 follow-up in the placebo group
(1.3  7.7%) and decreased in the mipomersen group (5.1 
7.5%). Results were similar when summarized by diabetes
status. Post-hoc analyses were performed to exploreL
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Figure 2 Change in LDL-C by Patient
LDL-C ¼ low-density lipoprotein cholesterol; PET ¼ primary efﬁcacy timepoint.correlations in liver parameters (Online Figs. 2A to 2D). As
expected, in the mipomersen group, there was a strong
correlation between the percent changes in apoB and LDL
cholesterol levels from baseline to the primary efﬁcacy
timepoint (r ¼ 0.95). Weaker associations were observed
between percentage change in apoB and change in liver fat
fraction (r ¼ 0.52), percent change in apoB and maximal
ALT level (r ¼ 0.44), and change in liver fat fraction and
maximal ALT level (r ¼ 0.52). Except for the close asso-
ciation of LDL cholesterol versus apoB (r ¼ 0.80), there was
no correlation in the placebo group.
Of the 54 patients who discontinued, 45 were in the
mipomersen group and 9 in the placebo group. AEs were
responsible for 28 (18%) of the discontinuations: 26
(25%) in the mipomersen group (7 because of liver
enzyme elevations and other AEs and 7 because of ISRs)
and 2 (4%) in the placebo group (Online Appendix B).
Discontinuation was approximately 11% of patients in
both groups secondary to withdrawal of consent. Serious
AEs occurred in 7 (7%) mipomersen and 4 (8%) placebo
patients. One death occurred in each group. The placebo
patient died during the treatment period from acute
myocardial infarction and cardiogenic shock. The mipo-
mersen patient was admitted to the hospital with acute
myocardial infarction and pneumonia 149 days after
completing treatment with mipomersen; the patient
died the following day from acute liver failure. The case
was adjudicated by 2 independent hepatologists, who
concluded that the cause of death was hepatic failure due to
acetaminophen toxicity and was unrelated to mipomersen.
Mipomersen had no adverse effect on renal function
(serum creatinine, estimated glomerular ﬁltration rate,
blood urea nitrogen), muscle (creatinine kinase), hema-
tology, glucose, or blood pressure, nor were any clinically
meaningful safety ﬁndings or trends in weight, vital signs,
or electrocardiographic parameters noted. T2DM status
did not alter the safety proﬁle in these parameters or in
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2 weeks from end of treatment for completers.
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2182relation to ISRs, FLS, or hepatic transaminase elevation or
steatosis.
Discussion
This is the ﬁrst phase 3 study of mipomersen in non-FH
patients with high cardiovascular risk due to prior CHD
events and/or concurrent T2DM. Mipomersen 200 mg
weekly signiﬁcantly reduced LDL cholesterol (by 36.9%)
compared with placebo (by 4.5%); the onset of action was as
early as 5 weeks. Consistent with its mechanism of action,
reductions in total cholesterol, non-HDL cholesterol, LDL/
HDL ratio, triglyceride, VLDL cholesterol, and Lp(a)
were also sizable; these effects were similar in patients with
diabetes and greater in women and older patients. TheTable 3 Effect of Treatment on Lipid Parameters in Patients With an
Subgroup Parameter
Placebo (Diabetic, n ¼ 29; Nondiabetic, n ¼ 21
Baseline PET % Change, Basel
Diabetic
LDL cholesterol (mg/dl) 118.7  31.8 109.8  28.5 4.89  1
ApoB (mg/dl) 113.4  25.8 107.6  23.1 3.56  1
Lp(a) (mg/dl) 49 (12, 98) 41 (15, 105) 0.0 (16.0,
Nondiabetic
LDL cholesterol (mg/dl) 128.1  46.8 118.1  42.9 4.04  3
ApoB (mg/dl) 119.0  35.7 111.1  32.5 4.83  2
Lp(a) (mg/dl) 22 (11, 66) 24 (10, 69) 7.1 (14.6,
Values are mean  SD or median (25th percentile, 75th percentile). *p < 0.001, mipomersen versus pla
and Lp(a) in the nondiabetic subgroup. P values were obtained by the Wilcoxon rank sum test for Lp(a)
Abbreviations as in Table 2.mipomersen dropout rate was 43%; AEs accounted for 25%
and included ISRs, FLS, and ALT increases. The placebo
dropout rate was 17%; AEs accounted for 4%. AEs affecting
tolerability included ISRs and FLS. ISRs did not occur at
every injection site or in all patients; 20% of mipomersen
patients had no ISRs. Anecdotally, ISRs lessened with pre-
dose oral diphenhydramine, icing, or topical lidocaine, and
FLS decreased with pre-dose nonsteroidal anti-inﬂammatory
drugs.
Either altering cholesterol secretion from the liver, as
would be expected by lowering the synthesis of apoB, or
another unspeciﬁed effect resulted in a mean change of
40.9  51.4 U/l in ALT from baseline to treatment end.
Mean ALT decreased to near baseline at the end of the
24-week treatment follow-up. Hepatic fat content and ALTd Without Diabetes
) Mipomersen (Diabetic, n ¼ 56; Nondiabetic, n ¼ 45)
ine to PET Baseline PET % Change, Baseline to PET*
9.4 115.5  22.2 67.0  28.3 40.53  26.51
4.86 113.4  18.9 67.1  28.2 40.89  22.26
13.8) 45 (14, 90) 34 (10, 61) 27.9 (43.7, 8.0)
0.15 131.5  38.9 85.6  34.5 32.44  26.88
2.17 121.7  31.0 80.0  32.6 33.33  24.76
18.8) 22 (6, 71) 13 (5, 39) 25.0 (37.6, 0.0)
cebo. P values were obtained using Student t tests for LDL cholesterol and apoB in both subgroups
in the diabetic subgroup because of deviations from normality.
Table 4
Adverse Events Reported and Laboratory
Abnormalities of Interest
Adverse Event
Placebo
(n ¼ 52)
Mipomersen
(n ¼ 105)
On-treatment adverse events
All events 42 (80.8%) 97 (92.4%)
Injection site reaction* 16 (30.8%) 82 (78.1%)
Flu-like symptomsy 11 (21.2%) 36 (34.3%)
ALT increased; LFT abnormality 7 (13.5%) 32 (30.5%)
Hepatic steatosis 2 (3.8%) 11 (10.5%)
ALT elevations on treatmentz
3  ULN and <5  ULN 0 (0.0%) 10 (9.5%)
5  ULN and <10  ULN 0 (0.0%) 4 (3.8%)
10  ULN 0 (0.0%) 1 (1.0%)
ALT 3  ULN, 2 consecutive
results 7days apart
0 (0.0%) 10 (9.5%)
3  ULN in presence
of bilirubin > ULN
0 (0.0%) 0 (0.0%)
Values are n (%). *Injection site reactions included injection site pain, erythema, pruritus, discol-
oration, hematoma, nodule, swelling, warmth, hemorrhage, edema, rash, induration, reaction,
vesicles, discomfort, inﬂammation, recall reaction, urticaria, dryness, exfoliation, pallor, and papule.
yFlu-like symptoms included inﬂuenza-like illness, inﬂuenza, pyrexia, chills, myalgia, arthralgia,
malaise, and fatigue. zNot all laboratory abnormalities were reported as adverse events.
ALT ¼ alanine aminotransferase; LFT ¼ liver function test; ULN ¼ upper limit of normal.
JACC Vol. 62, No. 23, 2013 Thomas et al.
December 10, 2013:2178–84 Mipomersen Reduces Atherogenic Lipoproteins
2183were correlated (r ¼ 0.52) with decreasing apoB, which was
strongly correlated with decreasing LDL (r ¼ 0.95). Mean
hepatic fat content decreased to near normal by 24 weeks
after treatment. It is not known if liver adaptation with the
potential to normalize hepatic fat would occur if mipo-
mersen had been continued longer. Adaptation has been
observed in mice receiving murine apoB antisense oligonu-
cleotide, whereby compensatory changes occur in pathways
of hepatic lipogenesis and fatty acid oxidation (15). Further
to this observation, an interim analysis of the 2-yearStudy
Figure 4 Change in ALT
Change in mean alanine aminotransferase (ALT) over time. BL ¼ baseline; ULN ¼ uppermipomersen open-label extension trial found hepatic fat
content to increase during the ﬁrst year in some patients but
to stabilize or decrease with continued treatment (16).
In the present study, which included patients with dia-
betes, there was no indication of clinical sequelae associated
with increases in ALT levels and/or liver fat content. Liver
biopsies obtained from mipomersen-treated subjects in other
studies have conﬁrmed steatosis and found minimal inﬂam-
mation with little to no ﬁbrosis (17). By extension, some but
not all patients with familial hypobetalipoproteinemia,
a lifelong condition of reduced apoB levels, have steatotic
livers. This secondary condition is not associated with insulin
resistance (18,19).
In this study, fewer patients completed treatment
compared with phase 3 trials of similar designs enrolling
patients with FH (8–10). One theory may be a reduced sense
of treatment urgency by physicians treating patients with-
out known genetic diseases and with lower baseline LDL
cholesterol levels. Additional safety studies in this population
and others will be necessary to fully explain high dropout
rates and potential opportunities to mitigate the occurrence
of AEs. A gradual increase in the dose of mipomersen is
being evaluated, for example, in the Study of the Safety and
Efﬁcacy of Two Different Regimens of Mipomersen in
Patients With Familial Hypercholesterolemia and Inade-
quately Controlled Low-Density Lipoprotein Cholesterol in
patients with heterozygous FH (NCT01475825). At this
time, mipomersen is approved for the treatment of homo-
zygous FH. The clinical development plan remains focused
on patients with genetically derived hypercholesterolemia,
with the greatest therapeutic potential in patients with
refractory FH. Week
ULN
limit of normal.
Table 5 Change From Baseline in Liver Fat Fraction by Diabetes Status and Treatment Cohort
Placebo Mipomersen
Diabetic
(n ¼ 30)
Nondiabetic
(n ¼ 22)
Diabetic
(n ¼ 58)
Nondiabetic
(n ¼ 47)
Baseline 2.7  7.4 (n ¼ 26) 3.4  6.9 (n ¼ 18) 3.9  7.4 (n ¼ 45) 0.8  6.0 (n ¼ 41)
Change from baseline to
end of treatment
1.3  8.7 (n ¼ 18) -0.2  8.6 (n ¼ 15) 17.5  13.5 (n ¼ 24) 14.3  8.3 (n ¼ 24)
Change from baseline to end of
off-treatment follow-up
0.5  7.5 (n ¼ 16) 2.4  8.1 (n ¼ 11) 5.7  9.0 (n ¼ 31) 4.4  5.3 (n ¼ 27)
Values for baseline liver fat fraction are mean  SD. Changes in liver fat fraction are mean nominal change  SD in percentage points. Liver MRI was not
available for all patients for reasons such as unreadable discs, inappropriate MRI settings, metal implants, and claustrophobia.
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Mipomersen represents a ﬁrst-in-class injectable antisense
therapy and provides the opportunity to use novel antisense
technology to modulate messenger ribonucleic acid trans-
lation without altering deoxyribonucleic acid. Mipomersen,
when added to lipid-lowering therapy, signiﬁcantly decreased
LDL cholesterol, apoB, Lp(a), and other atherogenic lipo-
proteins, potentially providing a new treatment option for
patients. The relatively high discontinuation rate attributed
to ISRs and FLS should encourage clinicians to focus on
managing patient expectations.
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APPENDIX
For a description of laboratory assessments and statistical analysis, a list
of patients discontinuing because of adverse events, and a list of study
investigators, please see the online version of this article.
